Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

NCT02998476 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02998476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02998476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
March 2, 2017
Completion date
February 5, 2021
Enrollment
60 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma